TEVA PHARMACEUTICAL INDUSTRIES LTD.

History

Year	Detail
1901	Teva established in Jerusalem as a small wholesale drug business by Chaim Salomon, Moshe Levin and Yitschak Elstein and is named S.L.E after its founders.
1939	During World War II, with the absence of imports, these plants are the sole source of pharmaceutical supplies for the local market and neighboring countries
1951	Teva begins trading on the Tel Aviv Stock Exchange (TASE) as the Teva Middle East Pharmaceutical Chemical Works Company Ltd.
1976	Teva, Assia, and Zori unite to create Israel’s largest drug maker - Teva Pharmaceutical Industries Ltd. Eli Hurvitz becomes first CEO of the merged company.
1977	Teva takes its first step abroad into Europe with the acquisition of Orphahell in the Netherlands.
1980	The Kfar Saba manufacturing facility is granted approval by the FDA in 1982.
1984	US Hatch-Waxman Act is passed, enabling Teva’s entry into generic medicines.
1985	Teva expands its U.S. market share through a joint venture with W.R. Grace, and the acquisition of Lemmon facilitates Teva’s entry into the U.S. market.
1988	Teva acquires Abic, the second largest pharmaceutical company in Israel, and completes the acquisition of Israeli API producer Plantex Ltd.
1994	Teva opens its flagship Teva-Tech API production facility at Ramat Hovav in Israel’s Negev desert.
1996	Acquisition of APS/Berk in the U.K. marks Teva’s first entry into a major Western European market.
1996	Teva’s innovative treatment for multiple sclerosis (MS), and the first specialty medicine for the company, is approved by the FDA.
2000	Acquisition of Novopharm Ltd., the second largest producer of generics in Canada, and its Hungarian subsidiary Human. Teva becomes the largest generic pharmaceutical company in North America.
2001	Teva’s innovative treatment for multiple sclerosis receives European Union approval.
2003	Acquisition of Regent Drugs Ltd. in India (renamed Teva API India Ltd.), which joins Teva’s API division.
2004	Acquisition of Sicor Inc. and its subsidiaries, bringing together Teva's successful oral dose generic drugs franchise with Sicor's leading generic injectable business, API and biogenerics capabilities.
2005	Teva's innovative drug for the treatment of Parkinson’s disease is approved for marketing in Israel and the EU. The treatment is later approved by the FDA in 2006.
2006	Acquisition of IVAX Corporation in the U.S. strengthens Teva’s worldwide presence through subsidiaries in Europe, Latin America and the Far East. The acquisition brings Teva a rich pipeline of generic and proprietary products in the complementary areas of respiratory, CNS, and oncology.
2008	Acquisition of Barr Pharmaceuticals in the U.S., including subsidiary PLIVA in Europe, enhances Teva’s leadership position in the US and key global markets, and strengthens Teva's portfolio and pipeline.
2010	Acquisition of Germany’s ratiopharm significantly increases Teva's market share in Europe, harnessing ratiopharm's excellent foundation for biosimilars, branded generics and tenders.
2011	Acquisition of Cephalon and its global subsidiaries strengthens Teva’s therapeutic diversification while providing a leadership position in branded and specialty pharmaceuticals
2012	Joint venture with Handok provides Teva with entrance into the South Korean pharmaceutical market and Teva begins trading on the NYSE (New York Stock Exchange).
2014	Acquisition of Labrys Biologics Inc. in the US opens the door for Teva to a strong and novel migraine prevention and treatment franchise within its CNS portfolio.
2015	Teva acquires Auspex, in order to strengthen Teva's core central nervous system franchise for treatment of movement disorders.
2016	Teva establishes a business venture with Takeda, Japan's largest pharmaceutical company leveraging Teva’s deep marketing expertise, commercial and medical excellence, with Takeda’s leading brand reputation and strong distribution presence in Japan.
2016	Teva acquires Actavis Generics, significantly expanding Teva’s generic product portfolio, R&D capabilities, product pipeline and global operational network.
2016	Teva acquires Anda Inc., a leading distributor of generic pharmaceuticals in the U.S.
2021	Teva celebrates 120 years since its founding, focused on being a global leader in generic and biopharmaceutical medicines, with a strong innovative portfolio.

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.